{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:40:21Z","timestamp":1792611621926,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007076","name":"Fondazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["MFAG 2014-15938"],"award-info":[{"award-number":["MFAG 2014-15938"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"University of Padua","doi-asserted-by":"publisher","award":["DOR 2023"],"award-info":[{"award-number":["DOR 2023"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009414","name":"Veneto Oncology Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG27152"],"award-info":[{"award-number":["IG27152"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["ID22759"],"award-info":[{"award-number":["ID22759"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["L02P03"],"award-info":[{"award-number":["L02P03"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003197","name":"Italian Medicines Agency","doi-asserted-by":"publisher","award":["FARM62MC97"],"award-info":[{"award-number":["FARM62MC97"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.esmoop.2025.105832","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:04:20Z","timestamp":1760144660000},"page":"105832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-9861","authenticated-orcid":false,"given":"M.V.","family":"Dieci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bisagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1255-0109","authenticated-orcid":false,"given":"S.","family":"Bartolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cavanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-6261","authenticated-orcid":false,"given":"A.","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Giotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rimanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7359-5410","authenticated-orcid":false,"given":"O.","family":"Garrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bertone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Cagossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4109-6769","authenticated-orcid":false,"given":"A.","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8969-638X","authenticated-orcid":false,"given":"F.","family":"Piacentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Orvieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6203-874X","authenticated-orcid":false,"given":"F.","family":"Miglietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Balduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.105832_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ctrv.2017.04.005","article-title":"Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: a meta-analysis of randomized controlled trials","volume":"57","author":"Solinas","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105832_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41523-024-00636-4","article-title":"Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade","volume":"10","author":"Liefaard","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105832_bib3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamaoncol.2022.6288","article-title":"Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2\/HER2-positive breast cancer: a correlative analysis of the CALGB 40601 and PAMELA trials","volume":"9","author":"Fernandez-Martinez","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105832_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jnci\/djy076","article-title":"Tumor-infiltrating lymphocytes in patients receiving trastuzumab\/pertuzumab-based chemotherapy: a TRYPHAENA substudy","volume":"111","author":"Ignatiadis","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105832_bib5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","article-title":"Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial","volume":"1","author":"Salgado","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105832_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105832_bib7","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105832_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamaoncol.2015.3239","article-title":"Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer","volume":"2","author":"Perez","year":"2016","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105832_bib9","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/jnci\/djz032","article-title":"Stromal tumor-infiltrating lymphocytes in NRG oncology\/NSABP B-31 adjuvant trial for early-stage HER2-positive breast cancer","volume":"111","author":"Kim","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105832_bib10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamaoncol.2024.6872","article-title":"Tumor-infiltrating lymphocytes and survival outcomes in early ERBB2-positive breast cancer","volume":"11","author":"Dieci","year":"2025","journal-title":"JAMA Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2025.105832_bib11","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1056\/NEJMsr1504363","article-title":"Breast-cancer screening\u2014viewpoint of the IARC Working Group","volume":"372","author":"Lauby-Secretan","year":"2015","journal-title":"N Engl J Med"},{"issue":"9945","key":"10.1016\/j.esmoop.2025.105832_bib12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0140-6736(14)60892-8","article-title":"Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5\u00b724 million UK adults","volume":"384","author":"Bhaskaran","year":"2014","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.esmoop.2025.105832_bib13","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1200\/JCO.2011.40.8666","article-title":"Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial","volume":"30","author":"Ewertz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105832_bib14","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.2009.27.2021","article-title":"Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial","volume":"28","author":"Sestak","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105832_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.37780","article-title":"Obesity and risk of recurrence in patients with breast cancer treated with aromatase inhibitors","volume":"6","author":"Harborg","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"35","key":"10.1016\/j.esmoop.2025.105832_bib16","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1200\/JCO.2016.68.4480","article-title":"Obesity and breast cancer prognosis: evidence, challenges, and opportunities","volume":"34","author":"Jiralerspong","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105832_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41523-021-00241-9","article-title":"The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data","volume":"7","author":"Modi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.esmoop.2025.105832_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115489","article-title":"Body mass index and weight changes in patients with HER2-positive early breast cancer: a sub-analysis of the APHINITY trial","volume":"223","author":"Dauccia","year":"2025","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105832_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.6004\/jnccn.2020.7606","article-title":"Body mass index and weight change in patients with HER2-positive early breast cancer: exploratory analysis of the ALTTO BIG 2-06 trial","volume":"19","author":"Martel","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105832_bib20","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/cncr.28051","article-title":"Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831","volume":"119","author":"Crozier","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2025.105832_bib21","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.3389\/fimmu.2019.01940","article-title":"The obesity paradox in cancer, tumor immunology, and immunotherapy: potential therapeutic implications in triple negative breast cancer","volume":"10","author":"Naik","year":"2019","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105832_bib22","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdy414","article-title":"Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study","volume":"29","author":"Conte","year":"2018","journal-title":"Ann Oncol"},{"issue":"32","key":"10.1016\/j.esmoop.2025.105832_bib23","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.23.00790","article-title":"Nine-week versus one-year trastuzumab for early human epidermal growth factor receptor 2\u2013positive breast cancer: 10-year update of the ShortHER phase III randomized trial","volume":"41","author":"Conte","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105832_bib24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/annonc\/mdz007","article-title":"Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer","volume":"30","author":"Dieci","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105832_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105832_bib26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12282-022-01355-z","article-title":"Associations of adiposity and weight change with recurrence and survival in breast cancer patients: a systematic review and meta-analysis","volume":"29","author":"Pang","year":"2022","journal-title":"Breast Cancer"},{"issue":"35","key":"10.1016\/j.esmoop.2025.105832_bib27","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1200\/JCO.2009.22.4436","article-title":"Underweight and breast cancer recurrence and death: a report from the Korean Breast Cancer Society","volume":"27","author":"Moon","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105832_bib28","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"446","key":"10.1016\/j.esmoop.2025.105832_bib29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105832_bib30","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/jnci\/djac126","article-title":"Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab","volume":"114","author":"Ligorio","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2025.105832_bib31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.canlet.2021.04.023","article-title":"Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer","volume":"511","author":"Ligorio","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.esmoop.2025.105832_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.critrevonc.2019.05.001","article-title":"Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives","volume":"139","author":"Vernieri","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105832_bib33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/jnci\/djaa090","article-title":"Body mass index and tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"113","author":"Floris","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"10258","key":"10.1016\/j.esmoop.2025.105832_bib34","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Murray","year":"2020","journal-title":"Lancet"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:14:15Z","timestamp":1773159255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2059702925017016"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105832","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105832"}}